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Background:  ECCO  essential  requirements  for quality  cancer  care  (ERQCC)  are  checklists  and  explanations
of  organisation  and  actions  that  are  necessary  to give  high-quality  care  to patients  who  have  a speciﬁc
tumour  type.  They  are  written  by European  experts  representing  all disciplines  involved  in cancer  care.
ERQCC  papers  give  oncology  teams,  patients,  policymakers  and  managers  an  overview  of  the  elements
needed  in  any  healthcare  system  to provide  high  quality  of care  throughout  the  patient  journey.  Refer-
ences  are  made  to clinical  guidelines  and other  resources  where  appropriate,  and  the  focus  is on  care  in
Europe.
Sarcoma:  essential  requirements  for  quality  care
• Sarcomas  –  which  can  be classiﬁed  into  soft  tissue  and  bone  sarcomas  –  are  rare, but  all  rare  can-
cers  make  up more  than  20%  of  cancers  in Europe,  and  there  are  substantial  inequalities  in  access  to
high-quality  care. Sarcomas,  of  which  there  are many  subtypes,  comprise  a particularly  complex  and
demanding  challenge  for  healthcare  systems  and  providers.  This  paper  presents  essential  requirements
for  quality  cancer  care  of  soft tissue  sarcomas  in  adults  and  bone  sarcomas.
• High-quality  care  must  only  be carried  out  in  specialised  sarcoma  centres  (including  paediatric  cancer
centres)  which  have  both  a core  multidisciplinary  team  and  an  extended  team  of  allied  professionals,  and
which  are  subject  to quality  and  audit  procedures.  Access  to  such  units  is far  from  universal  in  all  European
countries.
•  It is  essential  that,  to meet  European  aspirations  for high-quality  comprehensive  cancer  control,
healthcare  organisations  implement  the  requirements  in  this  paper,  paying  particular  attention  to  mul-
tidisciplinarity  and  patient-centred  pathways  from  diagnosis  and  follow-up,  to treatment,  to  improve
survival  and  quality  of  life  for  patients.
Conclusion: Taken  together,  the information  presented  in this  paper provides  a comprehensive  description
of  the essential  requirements  for establishing  a  high-quality  service  for soft  tissue  sarcomas  in adults  and
bone  sarcomas.  The  ECCO  expert  group  is aware  that  it  is not  possible  to propose  a ‘one  size  ﬁts  all’
system  for  all countries,  but  urges  that  access  to  multidisciplinary  teams  is guaranteed  to  all  patients
with  sarcoma.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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countri
cancer  
• Follow-
cally,  cology 110 (2017) 94–105
as members with sarcomas as their only, or one of their
y,  interest(s). On the basis of existing evidence, the expert
ecommends that for an institution to be considered as a
a centre it should treat at least 100 new sarcoma patients
oft tissue and bone) a year, although a threshold will
 on the structure of sarcoma networks in a region or coun-
 the distribution of expertise. Guidance from the National
e  for Health and Care Excellence (NICE) in England and
says that MDTs managing either soft tissue sarcoma or
rcoma should manage the care of at least 100 new patients
100 soft tissue and 50 bone sarcomas if the MDT  manages
pes), reﬂecting the more centralized nature of the UK’s
system (National Institute of Health and Care Excellence,
ote that owing to the rarity of paediatric cancer in general
e sarcoma in particular, minimum case volumes are nec-
 different between adult and paediatric treatment centres.
reNet,  a European Union information network on rare can-
s set out criteria for a sarcoma referral centre, and which
cussed in a paper, ‘Accreditation for centres of sarcoma
’ (Sandrucci et al., 2016).
 pathways and timelines
r sarcoma patients must be organised in pathways that
he patient’s journey from their point of view rather than
the healthcare system, and pathways must correspond to
 national and European evidence-based clinical practice
nes  on diagnosis, treatment and follow-up. (The Euro-
thway Association deﬁnes a care pathway as “a complex
ntion for the mutual decision making and organisation
 processes for a well-deﬁned group of patients during a
ﬁned  period”. This broad deﬁnition covers terms such as
, critical, integrated and patient pathways that are also
sed. See http://e-p-a.org/care-pathways). One source of
ation on care organisation is again NICE – it has published
ents including a manual on improving sarcoma out-
(National Institute of Health and Care Excellence, 2006), a
y (http://pathways.nice.org.uk/pathways/sarcoma), and a
 standard (see section on auditing, quality assurance and
tation). Pathways for soft tissue and bone sarcomas are
t,  and there are examples of such pathways (e.g. NHS Lon-
d South East Sarcoma Network, http://www.lsesn.nhs.uk/
a.html).
y  care practitioners, general surgeons and medical oncol-
re often referrers of those with suspected sarcoma and
mely access to reference centres. The maximum time for
intment for suspected adult cancer in England and Wales
eks, for example. NICE also recommends that children
ng people with suspected bone sarcoma on an x-ray are
d  within 48 h for an appointment with a specialist, and also
48 h for unexplained bone pain or swelling.
able times to report a diagnosis of sarcoma and the oppor-
o start treatment are crucial to timely treatment and to the
ng of patients. For example guidelines in the Netherlands
at the maximum time for diagnostic and staging proce-
 3 weeks, and the maximum time from ﬁrst appointment
treatment is 6 weeks, but shorter times should be aimed
 diagnosis, it must be clear to the patient which profes-
s responsible for each step in the treatment pathways and
following the patient during the journey (usually called a
nager or patient navigator) (Albreht et al., 2015). In many
es,  case managers during the main stages of treatment are
nurses.
up and survivorship are major issues in sarcoma. Typi-
are pathways include surveillance for cancer recurrence
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ients often have to seek help elsewhere for long term
ects of treatment, by going to both acute and commu-
ilities. Continuity and integration of all care by specialists
 implemented as gaps in long-term care can cause much
.
pean networks and societies
a centres must also participate in European sarcoma care
rch networks and societies. Such organisations play a cru-
 pooling expertise in all rare cancers. In sarcoma, research
clude the Soft Tissue and Bone Sarcoma Group at EORTC
n Organisation for Research and Treatment of Cancer),
uro Ewing Consortium; and professional societies include
ean Musculo-Skeletal Oncology Society (EMSOS) and the
e Tissue Oncology Society (CTOS).
lenge is sustainability of networks, and the rare cancer
ity has been lobbying for funding, including from the new
 Reference Networks (ERNs) (Wagstaff, 2016) (Blay et al.,
pplications for ERNs on rare cancers, including adult sar-
d childhood sarcomas, are currently being reviewed by
ean Commission; quality of care requirements will be an
t part of the work of these networks. The EU Joint Action
ancers will also support the creation of ERNs in the EU.
ultidisciplinary team
ent strategies for all patients must be decided on,
nd delivered as a result of consensus among a core mul-
ary team (MDT) that comprises the most appropriate
 for the particular diagnosis and stage of cancer, patient
istics and preferences, and with input from the extended
ity of professionals. The heart of this decision-making pro-
rmally a weekly or more frequent MDT  meeting where
ts are discussed with the objective of balancing the rec-
ations of clinical guidelines with the often formidable
ty of the individual sarcoma patient.
perly treat sarcomas it is essential to have a core MDT  of
 health professionals from the following disciplines:
gy/imaging
ntional  radiology
gy
erapy
l  and paediatric oncology
.
ore MDT  meets to discuss:
s after diagnosis and staging to decide on optimal treat-
es prior to local treatment (surgery, radiotherapy or
herapy (Gronchi et al., 2016))
s  after major treatment, usually surgery, to decide on fur-
atment and follow-up
s  with a recurrence during follow-up, or where changes to
nt programmes are indicated and have multidisciplinary
ce and/or planned deviations from clinical practice guide-
back
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ition, sarcoma radiologists should participate in meetings
screpancies between radiology and histology, as well as
, are discussed. When there is a discrepancy between a
st not based at the centre and the ﬁnal diagnosis, feed-
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biopsy isology 110 (2017) 94–105 99
uld be provided in an open and non-judgmental manner,
o raise standards among non-sarcoma radiologists.
care professionals from the following disciplines must
available whenever their expertise is required (the
d’ MDT):
r  medicine
gy pharmacy
ic  oncology
-oncology
ve care
litation and survivorship.
 is also an increasing sub-group of sarcomas that have a
redisposition. It may  be necessary soon to add a clini-
icist to the expanded MDT  to discuss options for genetic
d its results with patients and their families.
isions have to be documented in an understandable man-
should become part of the patient records. It is good
or decisions taken during MDT  meetings to be monitored,
tions reported back to the MDT  where there are problems.
ssential that all relevant patient data, such as pathology
eet quality standards and are available at the time of the
ting.
lines within the core MDT
ology/imaging
logy/imaging plays a critical role in diagnosing, staging and
 of sarcomas and personalised treatment. The role of the
st is to perform and interpret relevant imaging procedures
 the diagnosis of sarcomas.
tial requirements:
a  centres must have radiologists who  have signiﬁcant
se in the diagnosis, staging and follow-up of sarcomas
gists must have access to imaging modalities required for
ing and staging of sarcomas (e.g. ultrasound, radiographs,
I)
iologist must know when to refer a patient to nuclear
e. In that case (referral for bone scintigraphy, SPECT/CT
CT), nuclear medicine physicians and radiologists must
 allow joint patient management, reading and reporting
a  radiologists must collaborate with other specialist radi-
 (e.g. ENT radiologists and paediatric radiologists), as
as  affect a wide variety of organs and ages
g and histopathology ﬁndings should be discussed
r before making a diagnosis, to minimise diagnostic dis-
ies.  This is of particular importance in bone tumours and
-like lesions where conditions such as myositis ossiﬁcans
 misinterpreted as osteosarcoma on histopathology, or in
here the obtained biopsy may  not be representative of
ire lesion (Nuovo et al., 1992) (Noebauer-Huhmann et al.,
SLICED, 2007)
e sarcomas and other sarcomas in children, adolescents
ung adults, radiologists need experience with these age
.
ventional radiologyentional  radiology plays an important role in the diagno-
comas. Indeed, image-guided percutaneous core needle
 crucial in the delivery of a safe and efﬁcient sarcoma
100 emat
service, a
sarcomas
• Perform
posed  s
or  pulm
• Provide
with  m
therapi
• Perform
the MD
Essent
• Biopsie
• Interve
a sarco
2012),  
implem
• Interve
biopsy 
ments, 
• The  int
use  of 
metasta
therapy
2016)
• For  bon
cents  an
experie
4.3.  Path
Specia
comas gi
the morp
As diagn
enced pa
several co
have sub
treatmen
pling is 
tissue som
techniqu
material 
ESMO/Eu
Essent
• The  pat
the 201
tumour
tumour
et  al., 2
niques  
• Access  
sarily  o
and  pre
• There  m
the  bio
avoided
sarcom
Surg
urge
y in 
omas
treat
oma 
nts 
 be an
nost
en-b
rviv
eon i
sarco
he  ro
ordin
rform
ssen
rgery
colog
sarco
ont
oups
od p
ure 
sarco
scera
cera
e  blo
gans/
l  we
ve ex
mina
onst
ltidi
 able
ne  sa
st  c
ediat
ma  lo
bone
e  sar
he M
ing  
ma  i
ediat
nts  a
egio
rame
ere  m
cess 
r  bon
d  you
e  gro
rgery
Radi
s  desE. Andritsch et al. / Critical Reviews in Oncology/H
nd is the preferred biopsy technique in the diagnosis of
. The role of the interventional radiologist is to:
 image-guided percutaneous core needle biopsy of sup-
arcoma and to perform biopsy in case of unclear hepatic
onary lesions (Yang and Damron, 2004)
 expertise and support for combined therapies in patients
etastatic disease (e.g. transarterial treatments or ablative
es)
 appropriate minimally-invasive therapies according to
T’s decision.
ial requirements:
s  must be performed in sarcoma centres
ntional radiologists performing image-guided biopsies for
ma centre must have training and experience (Lee et al.,
have access to appropriate imaging equipment and must
ent  the WHO  Surgical Safety Checklist
ntional  radiologists must work with the MDT to plan the
to avoid the risk of ‘contamination’ of other compart-
which may  signiﬁcantly hamper surgical resection
erventional radiologist must discuss the role and propose
local ablative techniques for treating liver, lung or bone
ses  not amenable to, or combined with, surgery or radio-
 (Koelblinger et al., 2014) (Falk et al., 2015) (Jiang et al.,
e sarcoma and other sarcoma biopsies in children, adoles-
d young adults, interventional radiologists need sarcoma
nce  with these age groups.
ology
list pathologists are needed for diagnostic accuracy of sar-
ven their rareness, the large number of histotypes and
hological overlap between benign and malignant cases.
osis drives treatment options, a dedicated and experi-
thologist must be in the core MDT  from the start. In
untries there are panels of experienced pathologists that
stantial impact on diagnostic accuracy and subsequent
t results (Jansen-Landheer et al., 2009). Adequate sam-
needed for histology. While open biopsies offer more
etimes needed for molecular and immunohistochemical
es,  most centres use thick core needle biopsies to obtain
for histology both for soft tissue and bone tumours (The
ropean Sarcoma Network Working Group, 2014a,b).
ial  requirements:
hologist must establish a correct diagnosis according to
3 WHO  classiﬁcation, and in case of malignancy predict
 behaviour by stating the tumour grade. In soft tissue
s  this is done according to the FNLCC criteria (Neuville
014) and, when needed, by additional molecular tech-
(Hogendoorn et al., 2004)
to a molecular biologist must be guaranteed (not neces-
n site) and material for molecular testing must be set aside
served according to guidelines
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A
ust be a double-reading of the slides not only when
psy was done outside a sarcoma centre (which must be
 where possible) but also if the biopsy was done in the
a  centre.
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ery
ry is the mainstay of the treatment of sarcomas, espe-
primary disease. All non-metastatic adult-type primary
 are removed (resected) when possible as part of front-
ment; surgery alone can cure more than half of adult-type
patients (Gronchi et al., 2015) (Le Cesne et al., 2014). For
with metastatic disease and local recurrence, surgery can
 important part of treatment. Surgical margins are a major
ic factor concerning the risk of local recurrence in limbs,
loc resection is a determinant prognostic factor of over-
al in retroperitoneal sarcoma (RPS). The experience of the
s a prognostic factor of overall survival in RPS, and surgery
ma centre achieves better margins (Blay et al., 2016b).
le of the chief surgeon at a sarcoma centre is to:
ate  diagnostic procedures, surgery and perioperative care
 appropriate surgery as decided in the MDT.
tial requirements:
 must only be performed in a sarcoma centre by surgical
ists with signiﬁcant expertise in sarcomas
ma surgeon should carry out at least 3–4 procedures
h (30–40 a year) and they must participate in sarcoma
 and meetings at national and/or international level. It is
ractice for activity and outcomes to be published, and in
the expert group recommends that education/fellowship
ma management is required
l  surgical oncologists must be able to perform multi-
l  resections, including digestive and urologic organs in
c; plan (with a multidisciplinary surgical team) which
structures to sacriﬁce, with the potential for local con-
ighed against the potential for long-term dysfunction; and
pertise in procedures such as full-thickness thoracoab-
l wall, diaphragmatic and major vascular resection and
ruction. All these abilities may  also be available among
sciplinary surgical teams, but the sarcoma surgeon must
 to plan collaborations when necessary
rcomas must be operated on by a specialist surgeon. In
ases this is an orthopaedic surgeon, but can also be a
ric  surgeon or another surgeon depending on the sar-
cation. These surgeons must have signiﬁcant experience
 sarcoma treatment
coma centre should treat at least 100 patients per year
DT  manages both bone and soft tissue sarcoma patients.
to the rarity of paediatric cancer in general and bone sar-
n particular, this volume requirement does not apply to
ric  centres treating bone sarcomas in children, adoles-
nd young adults. The structure of sarcoma networks in
n or country and the distribution of expertise is another
ter inﬂuencing volume requirements
ust be an intensive care unit in sarcoma centres
to a plastic/reconstructive surgeon must be guaranteed
e sarcoma and other sarcomas in children, adolescents
ng adults, surgeons need sarcoma experience with these
ups. This is particularly important for bone sarcoma
 in young people who  have not reached skeletal maturity.
otherapy
cribed in the NCCN and ESMO guidelines (neo-)adjuvant
apy should be considered for non-metastatic sarcomas
ediate and high grade malignancy; it is much less rel-
 low grade sarcomas (von Mehren et al., 2016) (The
ropean Sarcoma Network Working Group, 2014b) (Haas
emat
et al., 20
oncologis
of radiati
techniqu
comas, ch
skull, spin
mas  as th
requires 
note that
local cont
cancer (D
Essent
• Radiati
and  esp
• They  m
(neo)ad
to surge
inform 
tions  to
• The  cen
IMAT  an
mould 
• The  cen
cation  p
Prospec
• The  cen
therapy
• For bon
and  you
with  th
4.6. Med
Medic
ease for a
and Ewin
GIST pati
Network 
often use
becoming
ular char
therapy m
mas, GIST
tissue sar
Given
takes ma
prepared
close to t
Essent
• Medica
cal  onco
the  beg
MDT  an
vention
• The  me
tise  in 
referen
must  be
• Medica
clinical
nationa
Nurs
urse
le w
rsity
sed k
i-mo
y (Sa
ssen
rses
e,  pe
e  pa
rough
rses
tient
vage
h-do
nt  rad
ey  m
inal  
trea
dy  a
atme
crosi
hen a
alth  
n,  ps
al., 2
iscip
Nucl
one  
CT w
as (m
) for
ging
t th
., 200
he ro
cts o
ire t
rithm
ssen
clea
le  to 
T/CT
 year
g,  an
nven
clea
ols  a
 in pl
rs is pE. Andritsch et al. / Critical Reviews in Oncology/H
12) (O’Sullivan et al., 2013). The role of the radiation
t is to determine and prescribe the most suitable dose
on to deliver in a particular case, and the method and
e by which this will be achieved. Except for Ewing sar-
ordomas and chondrosarcomas (derived from the base of
e and sacrum), radiotherapy is rarely used in bone sarco-
e only curative treatment, owing to radioresistance which
higher doses that increase side-effects. It is important to
 the quality of radiotherapy is signiﬁcantly associated with
rol, and quality assurance is mandatory for these types of
onaldson et al., 1998).
ial requirements:
on  oncologists must have expertise in sarcoma subtypes
ecially the probability of local recurrence per subtype
ust know the indications and contra-indications for
juvant and deﬁnitive radiotherapy, counsel patients prior
ry on the choice of neoadjuvant or adjuvant therapy, and
patients about acute and late side-effects, and interven-
 prevent them from happening or worsening
tre must have access to latest technologies such as IMRT,
d stereotactic (body) radiotherapy, with a state of the art
room to make personalised immobilisation devices
tre must be able to perform (daily) online setup veriﬁ-
rotocols and to react according to deviations observed.
tive quality assurance protocols must be in place
tre must organise treatment at a proton/heavy ion radio-
 centre if needed (DeLaney and Haas, 2016)
e sarcomas and other sarcomas in children, adolescents
ng adults, radiation oncologists need sarcoma experience
ese age groups.
ical and paediatric oncology
al therapy is needed in most patients with advanced dis-
ll sarcomas, in virtually all patients with osteosarcoma
g sarcoma, and in many high-risk soft tissue sarcoma and
ents with localized disease (The ESMO/European Sarcoma
Working Group, 2014b) (Neuville et al., 2014). It is also
d as front-line therapy before surgery. Medical therapy is
 highly variable depending on the pathologic and molec-
acteristics of the patient. Tumour response to medical
ay  present peculiar patterns, especially in bone sarco-
 and with some molecularly targeted therapies in soft
comas.
 the rarity of sarcomas, and that medical therapy often
ny months to administer, medical oncologists should be
 to work in health networks that care for adult patients
heir home.
ial  requirements:
l  therapy must be planned and administered by a medi-
logist, or a paediatric oncologist for young patients, from
inning of the patient’s journey, in collaboration with the
d closely following imaging (with regard also to uncon-
al  patterns of tumour response)
dical/paediatric oncologist must have specialised exper-
sarcomas with experience from working in a sarcoma
ce centre and/or a sarcoma reference network. Sarcomas
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ne a major component of their work
l/paediatric  oncologists must be involved in sarcoma
 research collaborative groups at a national and/or inter-
l  level.
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ing
s are the professionals who spend most time caring for
ith sarcoma, and require a range of roles, owing to the
 of tumour types and contexts of care. They need spe-
nowledge and skills to nurse people receiving complex,
dal sarcoma treatments, which have a high degree of mor-
muel, 2018).
tial  requirements:
 must conduct holistic nursing assessments to ensure
rsonalised and age-appropriate nursing care, and pro-
tient information and support to promote self-efﬁcacy
out the patient journey
 must provide intensive care following surgery; care for
s  who have had tissue conservation, bone ﬁxation, limb
 or surgical reconstruction; care for patients receiving
se chemotherapy; and care for patients receiving adju-
iation therapy, including brachytherapy (Lahl et al., 2008)
ust alleviate symptoms of sarcoma (e.g. pain, fatigue,
cord compression); prevent or manage side-effects
tment (e.g. radiation-induced skin injury, change in
ppearance and/or function); and care for patients with
nt-related complications (e.g. wound infection, ﬂap
s,  neutropenic sepsis, acute kidney injury)
cting as case managers, nurses must coordinate care with
professionals outside the core MDT, including rehabilita-
ychosocial, fertility and palliative care services (Prades
015).
lines within the expanded MDT
ear medicine
scintigraphy, SPECT/CT with various radiotracers, and
ith 18F FDG and 18F-FNa may  be indicated in certain sar-
usculoskeletal soft tissue sarcomas, bone sarcomas and
 prognosis, staging, treatment response evaluation, and
 (to conﬁrm limited or resectable disease before curative
erapy, and for local recurrence and metastases) (Nanni
9) (Gabriel and Rubello, 2016).
le of the nuclear medicine physician is to oversee all
f bone scintigraphy, SPECT/CT and PET/CT for patients who
hese procedures, including indications, multidisciplinary
s and management protocols.
tial requirements:
r  medicine physicians with expertise in PET must be avail-
the MDT. In 2016, most European hospitals have access to
 technology but it should preferably be on-site, be less than
s old and ready for integration in radiation treatment plan-
d have integrated PACS/RIS and updated workstations
tional nuclear medicine must also be available
r medicine must be able to perform daily veriﬁcation pro-
nd to react accordingly. Quality-assurance protocols must
ace. An option for ensuring the high quality of PET/CT scan-
rovided by the European Association of Nuclear Medicine)  through EARL accreditation (Boellaard et al., 2015)
e sarcomas and other sarcomas in children, adolescents
ung adults, nuclear medicine physicians need sarcoma
nce with these age groups.
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tric oncology
ird of soft tissue sarcoma patients are aged 65 or more,
must have access to geriatricians with oncology experi-
ile chronological age should not be a reason to withhold
therapy, goals may  vary signiﬁcantly according to age and
expert geriatric input.
le of the geriatric oncologist is to:
that older patients are screened for frailty
ate recommendations to other specialists about the need
onalised treatment for frail patients.
ial  requirements:
ic  oncologists must ensure all older patients are screened
simple risk-assessment frailty screening tool (Decoster
015) (Huisman et al., 2014) with whenever possible an
ion  of life expectancy to help prioritise medical inter-
s  (e.g. ePrognosis colorectal screening survey. http://
creening.eprognosis.org/screening)
tric oncology team (including geriatricians and other spe-
 must be available for all frail patients and their evaluation
ed  in MDT  meetings to offer personalised treatment
ic oncologists must ensure the early integration of pal-
care plans or geriatric interventions, especially for frail
s.
logy pharmacy
ogy  pharmacy plays a critical role in the care of sarcoma
given the importance of systemic treatment. The role of
ogy pharmacist is to:
ith the medical oncologist and/or paediatric oncologist to
 pharmaceutical treatment
ise  the preparation of oncology drugs.
ial requirements:
gy  pharmacists must work closely with medical/paediatric
ists. They must have experience with interactions with
rugs; experience with dose adjustments based on age,
d kidney function; and knowledge of complementary and
tive medicines. Oncology pharmacists must comply with
opean QuapoS guidelines (European Society of Oncology
cy,  2014)
gy  drugs must be prepared in the pharmacy or designated
ich meets the criteria pharmacies must comply with and
ing must take place under the supervision of the oncology
cist.
ho-oncology
 30% of sarcoma patients suffer from anxiety at diagno-
uring treatment and 20% suffer from clinical depression
and Canavarro Simões, 2010) (Paredes et al., 2012). Treat-
 seriously affect quality of life, especially for those who
or operations on limbs. Concerns about body image are
rly high in young people with bone sarcomas. Appropri-
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ducative programmes are needed for the main sarcoma
s. Supporting family members is also essential, particu-
elations of children, adolescents and young adults.
physiot
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• The  pal
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le of the psycho-oncologist is to:
 that psychosocial distress (National Comprehensive
 Network, 2003), and other psychological disorders and
social  needs, are identiﬁed by screening, and are consid-
 the MDT
e  effective communication between patients, family
rs  and healthcare professionals.
t  patients and family members to cope with multifaceted
 effects
te the reintegration of sarcoma survivors in school, work,
nd family environments through evidence-based psy-
cational interventions.
tial requirements:
s  must have access to a self-administered psychological
ent tool (‘distress thermometer’)
social  care must be provided at all stages of the disease and
tment for patients and their families and must be present
re comprehensive cancer care
iatric cancer, it is recommended that psychosocial support
s  play therapy and access to schooling.
ative care
 30–50% of patients with sarcomas die within 5 years
nosis, and there is an increasing need for palliative care
ut the disease trajectory, not only at end-of-life but at
 and during cancer treatments to manage distressing clin-
lications and symptoms and to improve the quality of life
ts and their families (Temel et al., 2010) (Hui et al., 2015)
 Abernethy, 2013) (Coindre et al., 2001). Palliative care, as
y the World Health Organization, applies not only at end
 throughout cancer care (see http://www.who.int/cancer/
/deﬁnition/en).
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